BiotechTube

Loncastuximab Tesirine and Epcoritamab

Phase 2Recruiting
2 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aggressive Diffuse Large B-cell Lymphoma

Conditions

Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B

Trial Timeline

Oct 15, 2025 → Jan 15, 2030

NCT ID
NCT07197307

About Loncastuximab Tesirine and Epcoritamab

Loncastuximab Tesirine and Epcoritamab is a phase 2 stage product being developed by AbbVie for Aggressive Diffuse Large B-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07197307. Target conditions include Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B.

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07197307Phase 2Recruiting

Competing Products

11 competing products in Aggressive Diffuse Large B-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapyJohnson & JohnsonPhase 2
39
Cabazitaxel + Carboplatin + Prednisone 5Mg + OlaparibAstraZenecaPhase 2
39
MidostaurinNovartisPhase 2
35
ImatinibNovartisPhase 2
35
Bendamustine and subcutaneous rituximabRochePhase 2
35
Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine SulfateBristol Myers SquibbPhase 1/2
36
Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine SulfateBristol Myers SquibbPhase 2
39
Vandetanib 300 mgSanofiPre-clinical
26
cemiplimab + odronextamabRegeneron PharmaceuticalsPhase 1
33
ZanzalintinibExelixisPhase 2
39
PRT2527 + Zanubrutinib + VenetoclaxPrelude TherapeuticsPhase 1
19